Fundraising Fox
/Companies
Sign in

Origami Therapeutics, Inc.

YC W22

San Diego, US · Founded 2015 · 4 employees · 3 known investors

Find your way into Origami Therapeutics, Inc.

Sign up to see every warm intro you have to Origami Therapeutics, Inc.

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Origami Therapeutics, Inc. team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Origami Therapeutics is a preclinical-stage biopharmaceutical company developing protein degrader therapeutics to treat neurodegenerative diseases, starting with Huntington's disease. The company uses a proprietary platform that harnesses the body's natural protein disposal system to degrade disease-causing proteins.

BiotechDeep TechHealthtechMedical DevicesTherapeuticsDrug discoveryUnited States of AmericaAmerica / Canada

Founders & leadership· Y Combinator alumni (W22)

Origami Therapeutics, Inc. was founded in 2015 by Beth Hoffman and Leslie Schulze.

BHBeth Hoffman
Beth HoffmanCo-founder · CEODr. Hoffman is a cell biologist with degrees from Wellesley College and Johns Hopkins University who held R&D executive roles at Vertex Pharmaceuticals, Amgen, and Eli Lilly before founding Origami Therapeutics to develop therapeutics for neurodegenerative diseases.
LSLeslie Schulze
Leslie SchulzeCo-Founder and CFOLeslie Schulze has over 20 years of experience in financial accounting and more than 13 years in biotech executive roles at early-stage pharmaceutical companies, where she has led finance, accounting, and administrative functions and secured venture capital and non-dilutive funding for R&D organizations.

Investors · 3

AJGreported

How we know: Y Combinator's founder network · Not right? Tell us

Impact AssetsreportedBethesda

How we know: Y Combinator's founder network · Not right? Tell us

Related companies · 7

Eris BiotechEris Biotech develops small-molecule drugs designed to block immune suppression mechanisms, allowing the immune system to attack solid tumors; the company is initially focusing on mesothelioma treatments.
Adventris PharmaceuticalsAdventris is a biotechnology company developing cancer immunotherapy treatments.
OrigamiOrigami is an AI-powered platform that helps sales teams identify and enrich prospective customers through intelligent prospecting and signal-based lead generation. The company serves modern go-to-market teams seeking to accelerate their sales workflows.
Engage BioEngageBio develops DNA-based medicines using proprietary non-viral delivery technology to achieve extended therapeutic expression from a single dose with low manufacturing complexity.
Origami RiskOrigami Risk provides risk management and insurance software for the risk and insurance industry, aiming to turn data into insights. The company works closely with clients and partners on solutions for risk and insurance operations.
Velorum TherapeuticsVelorium develops transformational medicines by combining scientific research with patient-focused collaboration. The company operates in the medical research and therapeutic development space.
Algen BiotechnologiesAlgen Biotechnologies discovers and develops small molecule therapeutics for cancer and inflammatory diseases using CRISPR, RNAi, and machine learning to decode functional gene networks and predict drug responses.

Companies working in the same space as Origami Therapeutics, Inc..

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase I2023$502.9K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Legal entities · 1

corporate structure
Origami Therapeutics, Inc.

In the news

Bio Investor Forum Panel, - Origami Therapeuticsorigamitherapeutics.com · Oct 2024Origami Therapeutics, Inc. selected as a CONNECT 2020 Cool Companyprnewswire.com · Jun 2020

Frequently asked questions

What does Origami Therapeutics, Inc. do?
Origami Therapeutics is a preclinical-stage biopharmaceutical company developing protein degrader therapeutics to treat neurodegenerative diseases, starting with Huntington's disease. The company uses a proprietary platform that harnesses the body's natural protein disposal system to degrade disease-causing proteins.
Who founded Origami Therapeutics, Inc.?
Origami Therapeutics, Inc. was founded by Beth Hoffman, Leslie Schulze in 2015.
Who are Origami Therapeutics, Inc.'s investors?
Origami Therapeutics, Inc.'s investors include Y Combinator, AJG, Impact Assets.
Where is Origami Therapeutics, Inc. headquartered?
Origami Therapeutics, Inc. is headquartered in San Diego, US.